RhumbLine Advisers’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $619K | Buy |
64,557
+7,818
| +14% | +$75K | ﹤0.01% | 2546 |
|
|
2025
Q1 | $356K | Buy |
56,739
+771
| +1% | +$4.83K | ﹤0.01% | 2790 |
|
|
2024
Q4 | $454K | Buy |
55,968
+5,110
| +10% | +$41.5K | ﹤0.01% | 2730 |
|
|
2024
Q3 | $920K | Sell |
50,858
-4,320
| -8% | -$78.1K | ﹤0.01% | 2303 |
|
|
2024
Q2 | $568K | Buy |
55,178
+8,075
| +17% | +$83.2K | ﹤0.01% | 2578 |
|
|
2024
Q1 | $500K | Sell |
47,103
-1,399
| -3% | -$14.9K | ﹤0.01% | 2669 |
|
|
2023
Q4 | $443K | Sell |
48,502
-8,035
| -14% | -$73.4K | ﹤0.01% | 2735 |
|
|
2023
Q3 | $586K | Buy |
56,537
+6,332
| +13% | +$65.7K | ﹤0.01% | 2519 |
|
|
2023
Q2 | $719K | Buy |
50,205
+17,444
| +53% | +$250K | ﹤0.01% | 2470 |
|
|
2023
Q1 | $234K | Buy |
32,761
+2,029
| +7% | +$14.5K | ﹤0.01% | 2700 |
|
|
2022
Q4 | $345K | Buy |
30,732
+1,805
| +6% | +$20.3K | ﹤0.01% | 2618 |
|
|
2022
Q3 | $321K | Buy |
28,927
+2,278
| +9% | +$25.3K | ﹤0.01% | 2699 |
|
|
2022
Q2 | $225K | Buy |
26,649
+6,681
| +33% | +$56.4K | ﹤0.01% | 2889 |
|
|
2022
Q1 | $272K | Buy |
19,968
+2,761
| +16% | +$37.6K | ﹤0.01% | 2671 |
|
|
2021
Q4 | $338K | Sell |
17,207
-247
| -1% | -$4.85K | ﹤0.01% | 2672 |
|
|
2021
Q3 | $560K | Buy |
17,454
+1,016
| +6% | +$32.6K | ﹤0.01% | 2497 |
|
|
2021
Q2 | $556K | Buy |
16,438
+5,048
| +44% | +$171K | ﹤0.01% | 2517 |
|
|
2021
Q1 | $428K | Sell |
11,390
-810
| -7% | -$30.4K | ﹤0.01% | 2561 |
|
|
2020
Q4 | $405K | Buy |
12,200
+1,280
| +12% | +$42.5K | ﹤0.01% | 2526 |
|
|
2020
Q3 | $400K | Sell |
10,920
-1,870
| -15% | -$68.5K | ﹤0.01% | 2388 |
|
|
2020
Q2 | $421K | Buy |
12,790
+1,367
| +12% | +$45K | ﹤0.01% | 2424 |
|
|
2020
Q1 | $295K | Buy |
11,423
+4,437
| +64% | +$115K | ﹤0.01% | 2417 |
|
|
2019
Q4 | $218K | Buy |
+6,986
| New | +$218K | ﹤0.01% | 2721 |
|